Type 2 daiabetes Chronic renal failure
Conditions
Interventions
Dulaglutide(0.75mg)/week for 3 weeks more then switch to Omarigliptin for 4 weeks
Sponsors
Minamiosaka hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Under 10.0% HbA1c for last 3 months or more 2.Agreement for the use of data 3.Under hemodialysis for 6 mouths or more
Exclusion criteria
Exclusion criteria: 1.Using other GLP1 analog formulation 2.Using other DPP4 inhibitor 3.Hypersensitivity for Dulaglutide and Omarigliptin 4.Severe ketosis,Diabetic coma and pre-coma,type 1 diabetes 5.Severe infection,pre and post operation ,severe trauma,such state with necessity of blood suger management by Insulin treatment 6.Pregnant woman,woman suspected of being pregnant,woman in breast-feeding 7.Patiants recognized to be inappropriate for study by medical basis of doctor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Glucose estimated by CGM | — |
Secondary
| Measure | Time frame |
|---|---|
| GA,height,weight,BP,HR,WBC,RBC,Hb,Ht,PLT,TG,HDL-CHO,LDL-CHO,AST,ALT,gamma-GTP,BUN,UA,CRN,Na,K,Cl | — |
Countries
Japan
Contacts
Public ContactNoriko Sakuma
Minamiosaka hospital Department of internal medicine
Outcome results
None listed